DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION

Allogeneic stem cell transplantation (alloHSCT) is effective curative option for a broad range of primary immunodeficiencies (PIDs). Hematopoietic chimerism monitoring in patients with various PIDs and its connection with the outcome of alloHSCT is of great interest. In this study 16 alloHSCT in pat...

Full description

Saved in:
Bibliographic Details
Main Authors: V. A. Lavrinenko, Y. E. Marejco, E. Y. Berezovskaya, M. V. Stegantseva, N. V. Minakowskaja, M. V. Belevtsev
Format: Article
Language:Russian
Published: ABV-press 2018-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/292
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241297115676672
author V. A. Lavrinenko
Y. E. Marejco
E. Y. Berezovskaya
M. V. Stegantseva
N. V. Minakowskaja
M. V. Belevtsev
author_facet V. A. Lavrinenko
Y. E. Marejco
E. Y. Berezovskaya
M. V. Stegantseva
N. V. Minakowskaja
M. V. Belevtsev
author_sort V. A. Lavrinenko
collection DOAJ
description Allogeneic stem cell transplantation (alloHSCT) is effective curative option for a broad range of primary immunodeficiencies (PIDs). Hematopoietic chimerism monitoring in patients with various PIDs and its connection with the outcome of alloHSCT is of great interest. In this study 16 alloHSCT in patients with PIDs were included. Three-year overall survival was 72.2 ± 12.0 %. Full donor chimerism (FDC) was achieved in 13 (81.25 %) patients. Prolonged persistence of mixed chimerism (MC) was observed in 3 (18.75 %) patients. In patients with MC in the peripheral blood, circulating T-cells are completely or predominantly of donor origin, whereas granulocytes are predominantly or completely recipient cells, and chimerism in B-cells differs significantly from 0 % chimerism to FDC. In patients with PIDs, engraftment of individual cell lines (split chimerism) could be observed. In some patients chimerism decreased during the first year after alloHSCT with its subsequent stabilization. Increasing MC is not associated with transplant rejection in PIDs. FDC in patients with PIDs provides restoration of all cell lines participating in the immune response regardless of the diagnosis, but it is associated with more frequent development of «graft-versus-host» disease (GVHD), which is a serious complication of alloHSCT and can lead to treatment-related mortality (TRM). MC/split chimerism, in which the frequency of development of GVHD is less, can also provide the formation of a full immune response and correction of other disease manifestations, but only when replacing defective cell lines according to the diagnosis.
format Article
id doaj-art-efbb2e6d56c544eeb015ce0f93ccef18
institution Kabale University
issn 1818-8346
2413-4023
language Russian
publishDate 2018-07-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-efbb2e6d56c544eeb015ce0f93ccef182025-08-20T04:00:13ZrusABV-pressОнкогематология1818-83462413-40232018-07-01132829210.17650/1818-8346-2018-13-2-82-92272DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATIONV. A. Lavrinenko0Y. E. Marejco1E. Y. Berezovskaya2M. V. Stegantseva3N. V. Minakowskaja4M. V. Belevtsev5Belarussian Research Center for Pediatric Oncology, Hematology and ImmunologyBelarussian Research Center for Pediatric Oncology, Hematology and ImmunologyBelarussian Research Center for Pediatric Oncology, Hematology and ImmunologyBelarussian Research Center for Pediatric Oncology, Hematology and ImmunologyBelarussian Research Center for Pediatric Oncology, Hematology and ImmunologyBelarussian Research Center for Pediatric Oncology, Hematology and ImmunologyAllogeneic stem cell transplantation (alloHSCT) is effective curative option for a broad range of primary immunodeficiencies (PIDs). Hematopoietic chimerism monitoring in patients with various PIDs and its connection with the outcome of alloHSCT is of great interest. In this study 16 alloHSCT in patients with PIDs were included. Three-year overall survival was 72.2 ± 12.0 %. Full donor chimerism (FDC) was achieved in 13 (81.25 %) patients. Prolonged persistence of mixed chimerism (MC) was observed in 3 (18.75 %) patients. In patients with MC in the peripheral blood, circulating T-cells are completely or predominantly of donor origin, whereas granulocytes are predominantly or completely recipient cells, and chimerism in B-cells differs significantly from 0 % chimerism to FDC. In patients with PIDs, engraftment of individual cell lines (split chimerism) could be observed. In some patients chimerism decreased during the first year after alloHSCT with its subsequent stabilization. Increasing MC is not associated with transplant rejection in PIDs. FDC in patients with PIDs provides restoration of all cell lines participating in the immune response regardless of the diagnosis, but it is associated with more frequent development of «graft-versus-host» disease (GVHD), which is a serious complication of alloHSCT and can lead to treatment-related mortality (TRM). MC/split chimerism, in which the frequency of development of GVHD is less, can also provide the formation of a full immune response and correction of other disease manifestations, but only when replacing defective cell lines according to the diagnosis.https://oncohematology.abvpress.ru/ongm/article/view/292chimerismwhite blood cell subpopulationsprimary immunodeficiencyallogeneic stem cell transplantationgraft-versus-host diseaseimmune reconstitutionchildren
spellingShingle V. A. Lavrinenko
Y. E. Marejco
E. Y. Berezovskaya
M. V. Stegantseva
N. V. Minakowskaja
M. V. Belevtsev
DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
Онкогематология
chimerism
white blood cell subpopulations
primary immunodeficiency
allogeneic stem cell transplantation
graft-versus-host disease
immune reconstitution
children
title DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
title_full DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
title_fullStr DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
title_full_unstemmed DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
title_short DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
title_sort donor chimerism in patients with primary immunodeficiency after allogeneic hematopoietic stem cells transplantation
topic chimerism
white blood cell subpopulations
primary immunodeficiency
allogeneic stem cell transplantation
graft-versus-host disease
immune reconstitution
children
url https://oncohematology.abvpress.ru/ongm/article/view/292
work_keys_str_mv AT valavrinenko donorchimerisminpatientswithprimaryimmunodeficiencyafterallogeneichematopoieticstemcellstransplantation
AT yemarejco donorchimerisminpatientswithprimaryimmunodeficiencyafterallogeneichematopoieticstemcellstransplantation
AT eyberezovskaya donorchimerisminpatientswithprimaryimmunodeficiencyafterallogeneichematopoieticstemcellstransplantation
AT mvstegantseva donorchimerisminpatientswithprimaryimmunodeficiencyafterallogeneichematopoieticstemcellstransplantation
AT nvminakowskaja donorchimerisminpatientswithprimaryimmunodeficiencyafterallogeneichematopoieticstemcellstransplantation
AT mvbelevtsev donorchimerisminpatientswithprimaryimmunodeficiencyafterallogeneichematopoieticstemcellstransplantation